<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795704</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0053</org_study_id>
    <nct_id>NCT00795704</nct_id>
  </id_info>
  <brief_title>Impact of Mulberry Leaf on Type 2 Diabetes</brief_title>
  <acronym>Mul-DM</acronym>
  <official_title>Effect of Mulberry Leaf Extract on Glycemic Durability in Non-insulin Dependent Diabetes Mellitus: a Double-blind, Randomized, Placebo-controlled Pilot Study (Mul-DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether mulberry leaf extract will help control
      blood sugar in patients with type 2 diabetes. We also want to look at the safety of mulberry
      leaf extract in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The methods for testing this hypothesis include: a 2-week placebo run-in, followed by a
      double-blind randomization into 2 groups: (1) mulberry leaf extract and (2) matching placebo.
      Evaluations of hemoglobin A1C (A1C) -- A measurement of blood glucose over the past 3 months
      -- will be done at baseline [before placebo run-in period] and 3 months. Evaluations of
      safety laboratories and adverse effect questionnaire will be done at 4 weeks and at 3 months
      following the randomization visit. Subjects will undergo a 2-week placebo run-in phase, and
      then will be divided into two groups: (1) mulberry leaf extract and (2) matching placebo. The
      subjects will ingest 1000 mg (#2 500 mg capsules) of standardized mulberry leaf extract
      (Nature-Gen, San Diego, CA) or matching placebo three times daily with meals for 3 months.
      Patients will be asked to monitor fasting morning blood glucose and 2-hour postprandial
      dinner blood glucose daily during the 2-week placebo run-in. To ensure compliance, only
      subjects compliant with both medication and monitoring instructions will be issued a 30-day
      supply of study medication at enrollment and the remainder at the 4-week safety visit. Each
      visit will consist of clinical examination, completed questionnaires, evaluation of
      self-monitoring blood glucose (SMBG), and donated blood for clinical laboratory tests.
      Standard recommendations for therapeutic lifestyle intervention will be given to both groups.
      All the clinical laboratory tests will be performed at the University of Mississippi Medical
      Center. All patients will receive identical 2-week placebo phase capsules, and then be
      randomized to each group using similar lookin
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>3 month minus baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reactions, Abnormal Metabolic Panel Levels, or Abnormal Liver Enzyme Levels</measure>
    <time_frame>Baseline, 1 month, and 3 months</time_frame>
    <description>Sodium (&gt;150 mmol/L), Potassium (&gt;5 mmol/L), Bicarbonate (&gt;34 mmol/L), Chloride (&gt;110 mmol/L), Serum Creatinine (&gt;1.2 mg/dL), Blood Urea Nitrogen (24 mg/dL), Calcium (&gt;11 mg/L), Alanine Aminotransferase (&gt;3 times baseline), Aspartate Aminotransferase (&gt;3 times baseline) were collected at baseline, 1 month, and 3 months. Self-Reported adverse drug reactions are also reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>2-hour postprandial SMBG reported. A negative value indicates a decrease from baseline. A positive value indicates an increase from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mulberry Leaf Extract</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mulberry Leaf Extract</intervention_name>
    <description>Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months</description>
    <arm_group_label>Mulberry Leaf Extract</arm_group_label>
    <other_name>Mulberry</other_name>
    <other_name>Morus indica L.</other_name>
    <other_name>Morus alba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 500 mg #2 capsules by mouth three times daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  No diabetes medication adjustments for at least 2 months

          -  Stable hemoglobin A1C [Between 7.0% to 8.0% (inclusive) and not varying by more than
             10% since prior visit; If no A1C exists prior to the current visit and no medication
             adjustments are made, the current A1C may used as the baseline]

        Exclusion Criteria:

          -  On insulin

          -  History of overt cardiovascular disease

          -  History of missed appointments or non-compliance with medications

          -  History of hepatic or renal insufficiency

          -  History of hemoglobinopathies

          -  Women of reproductive potential not on oral contraceptives

          -  Pregnant/nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Riche, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andallu B, Varadacharyulu NC. Gluconeogenic substrates and hepatic gluconeogenic enzymes in streptozotocin-diabetic rats: effect of mulberry (Morus indica L.) leaves. J Med Food. 2007 Mar;10(1):41-8.</citation>
    <PMID>17472465</PMID>
  </reference>
  <reference>
    <citation>Mudra M, Ercan-Fang N, Zhong L, Furne J, Levitt M. Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75 g sucrose by type 2 diabetic and control subjects. Diabetes Care. 2007 May;30(5):1272-4. Epub 2007 Feb 15.</citation>
    <PMID>17303787</PMID>
  </reference>
  <reference>
    <citation>Hansawasdi C, Kawabata J. Alpha-glucosidase inhibitory effect of mulberry (Morus alba) leaves on Caco-2. Fitoterapia. 2006 Dec;77(7-8):568-73. Epub 2006 Sep 22.</citation>
    <PMID>17071014</PMID>
  </reference>
  <reference>
    <citation>Zhong L, Furne JK, Levitt MD. An extract of black, green, and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers. Am J Clin Nutr. 2006 Sep;84(3):551-5.</citation>
    <PMID>16960168</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>April 16, 2012</results_first_submitted>
  <results_first_submitted_qc>June 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2012</results_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Riche</investigator_full_name>
    <investigator_title>Assistant Professor of Pharmacy Practice and Medicine</investigator_title>
  </responsible_party>
  <keyword>Herbal Supplement</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Mulberry</keyword>
  <keyword>Hemoglobin A1C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruted from April 2008 - Feb 2010 in University of Mississippi Cardiometabolic clinic.</recruitment_details>
      <pre_assignment_details>Two week placebo run-in</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Control Group</description>
        </group>
        <group group_id="P2">
          <title>Mulberry Leaf Extract</title>
          <description>500 mg #2 capsules three times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Control Group</description>
        </group>
        <group group_id="B2">
          <title>Mulberry Leaf Extract</title>
          <description>500 mg #2 capsules three times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="7"/>
                    <measurement group_id="B2" value="57.3" spread="5.5"/>
                    <measurement group_id="B3" value="56.7" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1C</title>
        <time_frame>3 month minus baseline</time_frame>
        <population>intention-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Control Group</description>
          </group>
          <group group_id="O2">
            <title>Mulberry Leaf Extract</title>
            <description>500 mg #2 capsules three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1C</title>
          <population>intention-to-treat</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.51"/>
                    <measurement group_id="O2" value="-0.26" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reactions, Abnormal Metabolic Panel Levels, or Abnormal Liver Enzyme Levels</title>
        <description>Sodium (&gt;150 mmol/L), Potassium (&gt;5 mmol/L), Bicarbonate (&gt;34 mmol/L), Chloride (&gt;110 mmol/L), Serum Creatinine (&gt;1.2 mg/dL), Blood Urea Nitrogen (24 mg/dL), Calcium (&gt;11 mg/L), Alanine Aminotransferase (&gt;3 times baseline), Aspartate Aminotransferase (&gt;3 times baseline) were collected at baseline, 1 month, and 3 months. Self-Reported adverse drug reactions are also reported.</description>
        <time_frame>Baseline, 1 month, and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Control Group</description>
          </group>
          <group group_id="O2">
            <title>Mulberry Leaf Extract</title>
            <description>500 mg #2 capsules three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reactions, Abnormal Metabolic Panel Levels, or Abnormal Liver Enzyme Levels</title>
          <description>Sodium (&gt;150 mmol/L), Potassium (&gt;5 mmol/L), Bicarbonate (&gt;34 mmol/L), Chloride (&gt;110 mmol/L), Serum Creatinine (&gt;1.2 mg/dL), Blood Urea Nitrogen (24 mg/dL), Calcium (&gt;11 mg/L), Alanine Aminotransferase (&gt;3 times baseline), Aspartate Aminotransferase (&gt;3 times baseline) were collected at baseline, 1 month, and 3 months. Self-Reported adverse drug reactions are also reported.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages</title>
        <description>2-hour postprandial SMBG reported. A negative value indicates a decrease from baseline. A positive value indicates an increase from baseline.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Intention-to-treat with data submitted baseline and final.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Control Group</description>
          </group>
          <group group_id="O2">
            <title>Mulberry Leaf Extract</title>
            <description>500 mg #2 capsules three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Self-Monitoring Blood Glucose (SMBG) Averages</title>
          <description>2-hour postprandial SMBG reported. A negative value indicates a decrease from baseline. A positive value indicates an increase from baseline.</description>
          <population>Intention-to-treat with data submitted baseline and final.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="36.3"/>
                    <measurement group_id="O2" value="3.6" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 and 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Control Group</description>
        </group>
        <group group_id="E2">
          <title>Mulberry Leaf Extract</title>
          <description>500 mg #2 capsules three times daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Warfarin intoxication after recent dose increase. Unrelated to study medication. Held study medication for 3 weeks per PCP, then resumed and completed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Upset</sub_title>
                <description>GERD, abdominal pain, gas, bloating, constipation</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>UTI, Influenza, skin infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <description>itching, watery eyes, sinus headache</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Riche</name_or_title>
      <organization>University of Mississippi Medical Center</organization>
      <phone>601-984-2640</phone>
      <email>driche@umc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

